Free tool
FAERS Monitor: Esomeprazole Strontium
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202342 or its brand name (Esomeprazole Strontium, Esomeprazole Strontium). Reports on generic versions are filed under their own applications.
Reports
19
Serious
11
58% of reports
Hospitalization
5
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death3
- diarrhoea3
- fatigue3
- abdominal pain2
- asthenia2
- constipation2
- cyst2
- dehydration2
- faecal volume increased2
- faecaloma2
- functional gastrointestinal disorder2
- intestinal obstruction2
- memory impairment2
- off label use2
- white blood cell count decreased2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2015 | 4 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,140 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| faecal volume increased | 2 | 4278.4 | 1150.0 | 4,792 |
| functional gastrointestinal disorder | 2 | 640.9 | 172.7 | 718 |
| faecaloma | 2 | 404.2 | 108.9 | 452 |
| cyst | 2 | 178.4 | 48.1 | 198 |
| intestinal obstruction | 2 | 58.7 | 15.8 | 63 |
| white blood cell count decreased | 2 | 20.4 | 5.5 | 20 |
| dehydration | 2 | 16.6 | 4.5 | 16 |
| memory impairment | 2 | 16.1 | 4.3 | 15 |
| constipation | 2 | 10.2 | 2.7 | 9 |
| abdominal pain | 2 | 9.5 | 2.6 | 8 |
| asthenia | 2 | 5.9 | 1.6 | 4 |
| diarrhoeaSignal | 3 | 5.1 | 1.8 | 7 |
| fatigueSignal | 3 | 4.3 | 1.5 | 5 |
| death | 3 | 3.9 | 1.4 | 4 |
| off label use | 2 | 2.5 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.